←
Paolo Provenzano660 posts
Paolo Provenzano avatar

Paolo Provenzano

@ppproven

#Bioengineer and #quantitative #biologist, dedicated to understanding and fighting #cancer. Professor, Dept. of #Biomedical #Engineering

◷ Joined October 2011▧ 42 Photos and videos
Sarah Boyle 👩🏻‍🔬🎀 avatar
⟳ Paolo Provenzano retweeted
Sarah Boyle 👩🏻‍🔬🎀@DrSarahBoyle·Mar 9

We are very excited to share our newest results, published in Science Advances: “Compressive stress-driven Piezo1 activation and Rho-ROCK mechanotransduction promote tumor progression via epigenetic mechanical memory”. doi.org/10.1126/sciadv.aeb12…

The Mark Foundation for Cancer Research avatar
⟳ Paolo Provenzano retweeted
The Mark Foundation for Cancer Research@TheMarkFdn·Feb 23

New in @ScienceMagazine: Endeavor Award team members @SageJulien and K. Christopher Garcia have engineered "trikines"—synthetic cytokines that mix & match receptor signals to rewire immune cells. The result? Better tumor control & far less toxicity. science.org/doi/10.1126/scie…

Cancer Cell avatar
⟳ Paolo Provenzano retweeted
Cancer Cell@Cancer_Cell·Jan 30

Online Now: Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance dlvr.it/TQflcw

Post attachment
NYU Langone Health avatar
⟳ Paolo Provenzano retweeted
NYU Langone Health@nyulangone·Jan 28

We’re excited to announce that Anirban Maitra, MD (@Aiims1742)—a pre-eminent physician-scientist whose work has widely influenced the field of pancreatic cancer research—has been appointed the new director of @Perlmutter_CC here at NYU Langone. For more: bit.ly/4t2xDD2

Post attachment
Oscar Tahuahua avatar
⟳ Paolo Provenzano retweeted
Oscar Tahuahua@drtahuahua·Jan 28

Pancreatic ductal adenocarcinoma needs better RAS inhibitors. But that alone will not be enough. In this preclinical study KRAS blockade predictably activates EGFR and STAT3. As long as one escape route remains open, pancreatic tumors persist. Upfront triple inhibition of RAS (daraxonrasib), EGFR (afatinib) and STAT3 (SD36) achieved complete and durable tumor regression with no relapse beyond 200 days The signal is strong, but the message is clear: even if RASolute-302 (phase 3) 🔜is positive, RAS monotherapy will not be sufficient, especially in metastatic PDAC. Progress in RAS driven cancer depends on controlling resistance safely. pnas.org/doi/10.1073/pnas.25… @OncoAlert

Post attachmentPost attachmentPost attachment
Thomas R. Cox avatar
⟳ Paolo Provenzano retweeted
Thomas R. Cox@thomasrcox·10 Dec 2025

We're looking for a Research Assistant / Senior Research Assistant to join our team. If you're interested in studying the extracellular matrix and tumour microenvironment in cancer, then get in touch. Applications will be reviewed on a rolling basis. garvan.wd3.myworkdayjobs.com…

Post attachment
Catharine avatar
⟳ Paolo Provenzano retweeted
Catharine@DrCatharineY·17 Oct 2025

Just in case any one is wondering: Biomedical scientists spend an average of 12 years in training before reaching an independent position. That is more than most medical residences.

Post attachment
Lucia Borriello avatar
⟳ Paolo Provenzano retweeted
Lucia Borriello@luciaborriell·3 Sep 2025

🚨 Exciting Opportunity Alert! 🚨 Are you passionate about understanding why cancer patients relapse and uncovering the secrets of tumor dormancy and metastasis? Join our dynamic lab @templemedschool and @FoxChaseCancer ✨ Please RT to spread the word! ✨

Post attachment